

## Special Issue

# Asthma: From Phenotypes to Personalized Medicine

### Message from the Guest Editor

Asthma is a heterogenous disease of the airways with a high prevalence worldwide and characterized by chronic inflammation. The aim of asthma management is the control of the disease, and the cornerstone of asthma treatment is inhaled corticosteroids. As asthma becomes less well-controlled and more severe (moderate-to-severe), medications are more or less effective in particular phenotypes. Phenotypes and endotypes are known, respectively, as pathologic and molecular features that might not be directly associated with each other but may define a better response to treatment, and that is important from a clinical point of view. Accordingly, it has become necessary to define the phenotype of an asthmatic patient mainly based upon biomarkers and clinical features, and this has led to treatable traits and personalized medicine. Each asthmatic, and especially severe ones, is evaluated in terms of their phenotype, followed by the initiation of a treatment regimen that would be more effective in improving symptoms and/or reducing exacerbations, both of which are considered measures of control.

### Guest Editor

Prof. Dr. Petros Bakakos

1st University Department of Respiratory Medicine, National and Kapodistrian University of Athens, Athens, Greece

### Deadline for manuscript submissions

closed (30 April 2022)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/96488](https://mdpi.com/si/96488)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).